SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MGNX -- MacroGenics
An SI Board Since November 2013
Posts SubjectMarks Bans Symbol
188 21 0 MGNX
Emcee:  scaram(o)uche Type:  Moderated
Introduction Market Data Compact
CD123-related abstract (preclinical) coming up at ASH, so maybe it's time for a thread. DART is a very old concept.... I was one of the first to try it, but the original concept came from Dartmouth and served as the foundation science for Medarex.

MGD006, Servier has right to license for some geographies.....

ash.confex.com

One more ASH abstract, not from MGNX.......

ash.confex.com

Pointer to the pipeline chart, website.....

macrogenics.com

Go!
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
188Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART &#scaram(o)uche-9/7/2021
187Final analysis of the trial shows no significant benefit over T. ir.macrogenicsscaram(o)uche-9/7/2021
186>> I personally believe that marg would beat trastuzumab by wide margin inscaram(o)uche-6/11/2020
185Nice gain for those who have (had) *fate* in managements! finance.yahoo.comMiljenko Zuanic-5/6/2020
184AZN: trastuzumab deruxtecan (after 6-line of therapy, progressed on anti-her2) Miljenko Zuanic-12/20/2019
183Indoor season. Out of here.scaram(o)uche-12/19/2019
182>> Regards the 158F-negative...stopped following MGNX, is that for gastricscaram(o)uche-12/19/2019
181Yes and no, but that's the small fraction of breast patients which show no rscaram(o)uche-12/19/2019
180Many things are in tunacitibin favor right now,,,, breakthrough, clear path forwMiljenko Zuanic-12/19/2019
179Won't be long before tucatinib is approved. If I were a CD16A 158F-positivescaram(o)uche-12/19/2019
178Marg BLA....is there any chance for approval??? seekingalpha.comMiljenko Zuanic-12/19/2019
177<PS: I am pissed that my 32.6 order did not went true....other than that, fewMiljenko Zuanic-6/5/2019
176>> n=62 for the V/V population vs. 437 for FF/FV << Conference callscaram(o)uche-6/4/2019
175As I've mentioned on more that one occasion, I have held very few shares....scaram(o)uche16/4/2019
174I am out!Miljenko Zuanic-6/4/2019
173TERRIBLE OS KM curve: twitter.comMiljenko Zuanic-6/4/2019
172finance.yahoo.com Marg positive, not very big but posite, on several measuremenMiljenko Zuanic-5/16/2019
171Marg pre-clinical at AACR-2019: ir.macrogenics.comMiljenko Zuanic-4/3/2019
170AstraZeneca and Daiichi Sankyo enter collaboration for novel HER2-targeting antinigel bates-3/29/2019
169If they want any return for Merg, they need to accelerate filling. Competitor: dMiljenko Zuanic-3/28/2019
168RE: Teplizumab (anti-CD3 for autoimmune T1D) : endpts.com clinicaltrials.govMiljenko Zuanic-3/28/2019
167For the first February 15 days, short interest is reduced by 1.5m shares (35%), Miljenko Zuanic-3/2/2019
166Manufacturing We currently manufacture our drug substance for our clinical trialMiljenko Zuanic-2/27/2019
165Many *street oncology experts* were quick to point that luck of absolute numbersMiljenko Zuanic-2/25/2019
164FUCx WG, and many others, who think that by blocking me will gain something, insMiljenko Zuanic-2/24/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News